1.	Effect of Lactobacillus Brevis CD2 in Prevention of Radio-chemotherapy Induced Oral Mucositis in Head and Neck Cancer Phase: Phase IV Type: Supportive care Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: CD2 AIRO, NCT01707641
2.	CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000727295, NCCTG-N11C5, N11C5, NCT01545687
3.	A Phase III Study of Efficacy of Lactobacillus CD2 Lozenges in Preventing High-Dose Chemotherapy Induced Oral Mucositis in Patients Undergoing Myeloablative Hematopoietic Stem Cell Transplantation Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: P 1201, NCT01797952